Free Account Opening + AMC Free Demat
Loading...

Concord Biotech IPO vs Senco Gold IPO

Comparision between Concord Biotech IPO and Senco Gold IPO.

IPO Details

Concord Biotech IPO is a Mainline Book Built Issue IPO proposed to list at BSE, NSE while Senco Gold IPO is a Mainline Book Built Issue proposed to list at BSE, NSE.

Issue Size and Price

The total issue size of Concord Biotech IPO is up to ₹1,551.00 Cr whereas the issue size of the Senco Gold IPO is up to ₹405.00 Cr. The final issue price of Concord Biotech IPO is ₹741.00 per share and of Senco Gold IPO is ₹317.00 per share.

  Concord Biotech IPO Senco Gold IPO
Face Value ₹1 per share ₹10 per share
Issue Price (Lower) ₹705.00 per share ₹301.00 per share
Issue Price (Upper) ₹741.00 per share ₹317.00 per share
Issue Price (Final) ₹741.00 per share ₹317.00 per share
Discount (Retail)
Discount (Employee) ₹70.00 per share
Market Lot Size 20 shares 47 shares
Fresh Issue Size 85,17,350 shares
Fresh Issue Size (Amount) up to ₹270.00 Cr
OFS Issue Size 2,09,25,652 shares 42,58,675 shares
OFS Issue Size (Amount) up to ₹1,551.00 Cr up to ₹135.00 Cr
Issue Size Total 2,09,25,652 shares 1,27,76,025 shares
Issue Size Total (Amount) up to ₹1,551.00 Cr up to ₹405.00 Cr

IPO Timetable

Concord Biotech IPO opens on Aug 04, 2023, while Senco Gold IPO opens on Jul 04, 2023. The closing date of Concord Biotech IPO and Senco Gold IPO is Aug 08, 2023, and Jul 06, 2023, respectively.

  Concord Biotech IPO Senco Gold IPO
Anchor Bid Date Aug 03, 2023 Jul 03, 2023
Issue Open Aug 04, 2023 Jul 04, 2023
Issue Close Aug 08, 2023 Jul 06, 2023
Basis Of Allotment (Tentative) Aug 11, 2023 Jul 11, 2023
Initiation of Refunds (Tentative) Aug 14, 2023 Jul 12, 2023
Credit of Share (Tentative) Aug 17, 2023 Jul 13, 2023
Listing date (Tentative) Aug 18, 2023 Jul 14, 2023
Anchor Lockin End date 1 Sep 10, 2023 Aug 10, 2023
Anchor Lockin End date 2 Nov 09, 2023 Oct 09, 2023

Financials

Concord Biotech IPO P/E ratio is 32.29, as compared to Senco Gold IPO P/E ratio of 15.53.

  Concord Biotech IPO Senco Gold IPO
Financial
Concord Biotech IPO Financial Information (Restated Consolidated)
Period Ended31 Mar 202131 Mar 202231 Mar 2023
Assets1,182.551,312.801,513.98
Revenue630.75736.35888.48
Profit After Tax234.89174.93240.08
Net Worth999.371,103.221,290.00
Reserves and Surplus
Total Borrowing86.3560.5931.24
Amount in ₹ Crore
Senco Gold Limited Financial Information (Restated Consolidated)
Period EndedTotal AssetsTotal RevenueProfit After TaxNet WorthReserves and SurplusTotal Borrowing
31-Mar-211,559.302,674.9261.48602.51536.53532.44
31-Mar-222,100.193,547.41129.10725.77659.46862.97
31-Mar-232,905.324,108.54158.48944.97876.271,177.17
Amount in ₹ Crore
Promoter Shareholding (Pre-Issue) 44.08% 76.92%
Promoter Shareholding (Post-Issue) 44.08% 68.48%
P/E Ratio 32.29 15.53
Market Cap ₹7752.06 Cr. ₹2462.00 Cr.
ROE 20.06%% 18.9%%
ROCE 24.27%% 14.2%%
Debt/Equity 1.25
EPS ₹20.79 ₹22.93
RoNW 20%% 18.96%%

Shares Offered

In the Concord Biotech IPO retail investors (RII) are offered 73,20,479 shares while in Senco Gold IPO retail investors are offered 73,20,479 shares. Qualified institutional buyers (QIB) are offered 41,83,130 shares in Concord Biotech IPO and 25,55,203 shares in Senco Gold IPO.

  Concord Biotech IPO Senco Gold IPO
Anchor Investor Reserveration 62,74,695 shares 38,32,807 shares
Market Maker Reserveration
QIB 41,83,130 shares 25,55,203 shares
NII 31,37,348 shares 19,16,404 shares
RII 73,20,479 shares 44,71,609 shares
Employee 10,000 shares 0 shares
Others
Total 1,46,50,957 shares 89,43,216 shares

Bids Received (Subscription)

Concord Biotech IPO subscribed 24.87x in total, whereas Senco Gold IPO subscribed 77.25x.

  Concord Biotech IPO Senco Gold IPO
QIB (times) 67.67x 190.56x
NII (times) 16.99x 68.44x
Big NII (times) 19.30x 72.05x
Small NII (times) 12.37x 61.23x
RII (times) 3.78x 16.28x
Employee (times) 24.48x
Other (times)
Total (times) 24.87x 77.25x

Comments

Add a public comment...